Trial Profile
The efficacy and safety of arsenic trioxide added transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jan 2014
Price :
$35
*
At a glance
- Drugs Arsenic trioxide (Primary) ; Epirubicin
- Indications Liver cancer
- Focus Therapeutic Use
- 30 Sep 2012 Status changed from not yet recruiting to completed as reported by Chinese Clinical Trial Register.
- 15 Sep 2009 New trial record